Lisata Therapeutics Files 8-K
Ticker: LSTA · Form: 8-K · Filed: Jun 26, 2025 · CIK: 320017
| Field | Detail |
|---|---|
| Company | Lisata Therapeutics, Inc. (LSTA) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, corporate-history
Related Tickers: LISATA
TL;DR
Lisata Therapeutics (LISATA) filed an 8-K on 6/26/25, mostly Reg FD and financials. Formerly Caladrius/NeoStem.
AI Summary
On June 26, 2025, Lisata Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc.
Why It Matters
This 8-K filing provides important updates and disclosures regarding Lisata Therapeutics, Inc.'s financial and regulatory status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for disclosures and exhibits, not indicating immediate operational or financial distress.
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Registrant
- CALADRIUS BIOSCIENCES, INC. (company) — Former company name
- NeoStem, Inc. (company) — Former company name
- June 26, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for Lisata Therapeutics, Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What was Lisata Therapeutics, Inc. previously known as?
Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and prior to that, NeoStem, Inc.
On what date was this 8-K report filed?
This 8-K report was filed on June 26, 2025.
In which state is Lisata Therapeutics, Inc. incorporated?
Lisata Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Lisata Therapeutics, Inc.?
The principal executive office address for Lisata Therapeutics, Inc. is 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding LISATA THERAPEUTICS, INC. (LSTA).